Research programme: immunomodulatory therapeutics - Innovimmune Biotherapeutics

Drug Profile

Research programme: immunomodulatory therapeutics - Innovimmune Biotherapeutics

Alternative Names: INV-17; INV-25; INV-33; INV-71; INV-88

Latest Information Update: 09 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovimmune Biotherapeutics
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Hepatoprotectants; Neuroprotectants; Small molecules
  • Mechanism of Action Immunomodulators; Macrophage migration inhibitory factor inhibitors; Nuclear receptor subfamily 1 group F member 3 antagonists; Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Malignant melanoma; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Research Atopic dermatitis; Autoimmune disorders; Cancer; Non-alcoholic steatohepatitis
  • No development reported Multiple sclerosis
  • Discontinued Age-related macular degeneration; Asthma; Atherosclerosis; Inflammation; Inflammatory bowel diseases; Metabolic disorders

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO)
  • 16 Feb 2018 Pharmacodynamics data from a preclinical trial in Malignant melanoma presented at the 76th Annual Meeting of the American Academy of Dermatology (AAD-2018)
  • 16 Feb 2018 Preclinical trials in Alzheimer's disease in USA (PO) (Innovimmune Biotherapeutics pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top